Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$132.15

-0.45 (-0.34%)

08:58
07/18/17
07/18
08:58
07/18/17
08:58

Johnson & Johnson says on track to accelerate launch of new products

Says filling key portfolio gaps. Says making good progress on near-term priorities, continue to advance long-term drivers.

  • 18

    Jul

  • 09

    Aug

JNJ Johnson & Johnson
$132.15

-0.45 (-0.34%)

06/14/17
RHCO
06/14/17
NO CHANGE
RHCO
Eli Lilly has positive read through from J&J data, says SunTrust
SunTrust analyst John Boris says that data for Johnson & Johnson's (JNJ) Invokana for diabetes represented a best-case scenario for Eli Lilly (LLY). J&J's drug "significantly reduced the combined risk of cardiovascular death, myocardial infarction and nonfatal stroke in diabetes patients at risk for or with a history of CV diseases," and its efficacy on CV death is positive for the SGLT-2 class, to which Eli Lilly's Jardiance also belongs, according to the analyst. But the data leaves Jardiance, which reduced CV death by a statistically significant 38% versus Invokana's non-significant 13%, as the best in the class, wrote the analyst, who reiterates a $101 price target and a Buy rating on Eli Lilly.
06/20/17
ADAM
06/20/17
NO CHANGE
Target $10
ADAM
Buy
Novadaq competing bids possible if not probable, says Canaccord
Canaccord analyst Jason Mills noted Novadaq (NVDQ) received an acquisition offer from Stryker (SYK) at a much greater equity value than what the company was trading at prior to the bid. Although he thinks Stryker is the most logical buyer of the franchise, he thinks there are several other potential acquirers, including Medtronic (MDT), Johnson & Johnson (JNJ) and Intuitive Surgical (ISRG), in that order. Mills believes this is a good exit for the company and that Stryker is getting a good asset. Mills maintains his Buy rating and $10 price target on Novadaq shares.
06/27/17
06/27/17
NO CHANGE

Large cap pharma could benefit from upcoming executive order, says Wells Fargo
Wells Fargo says that, based on press reports, large cap pharma could benefit from President Trump's upcoming executive order on drug pricing. The firm says the articles indicate that the order will not create major reforms or do anything to lower consumers' costs or solve current pricing issues. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/14/17
WELS
07/14/17
NO CHANGE
WELS
Underperform
J&J approval another negative for Valeant, says Wells Fargo
Wells Fargo analyst David Maris says Valeant Pharmaceuticals (VRX) has a new competitor in the psoriasis space after the FDA yesterday approved Tremfya from Johnson & Johnson (JNJ). The news is another negative for Valeant, which is about to launch its own psoriasis treatment, Siliq, in the second half of 2017, Maris tells investors in a research note. With Talz from Eli Lilly (LLY), Humira from AbbVie (ABBV), Cosentyx from Novartis (NVS) and now J&J as a new competitor, Valeant is unlikely to be competitive in the psoriasis market, Maris contends. He believes his peak sales estimate of $250M for Siliq may prove optimistic given the competition. Maris an Underperform rating on Valeant with a $9 price target. The drugmaker closed yesterday at $17.29.

TODAY'S FREE FLY STORIES

COH

Coach

$48.08

-0.07 (-0.15%)

08:52
07/21/17
07/21
08:52
07/21/17
08:52
Upgrade
Coach rating change  »

Coach upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INDB

Independent Bank

$66.35

-0.35 (-0.52%)

08:52
07/21/17
07/21
08:52
07/21/17
08:52
Upgrade
Independent Bank rating change  »

Independent Bank upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

AKBA

Akebia

, MACK

Merrimack

$1.30

0.02 (1.56%)

08:51
07/21/17
07/21
08:51
07/21/17
08:51
Periodicals
Former Akebia employee faces losing bail in insider trading case, Reuters says »

Schultz Chan, former…

AKBA

Akebia

MACK

Merrimack

$1.30

0.02 (1.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMC

AMC Entertainment

$20.60

0.75 (3.78%)

08:51
07/21/17
07/21
08:51
07/21/17
08:51
Initiation
AMC Entertainment initiated  »

AMC Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 05

    Sep

SIX

Six Flags

$56.28

-1.01 (-1.76%)

08:50
07/21/17
07/21
08:50
07/21/17
08:50
Initiation
Six Flags initiated  »

Six Flags initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

LYV

Live Nation

$36.38

-0.01 (-0.03%)

08:50
07/21/17
07/21
08:50
07/21/17
08:50
Initiation
Live Nation initiated  »

Live Nation initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNP

Union Pacific

$106.14

-1.7 (-1.58%)

08:50
07/21/17
07/21
08:50
07/21/17
08:50
Recommendations
Union Pacific analyst commentary  »

Market ignorning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

MTN

Vail Resorts

$206.11

0.09 (0.04%)

08:50
07/21/17
07/21
08:50
07/21/17
08:50
Initiation
Vail Resorts initiated  »

Vail Resorts initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$26.69

-0.25 (-0.93%)

08:49
07/21/17
07/21
08:49
07/21/17
08:49
Hot Stocks
Breaking Hot Stocks news story on General Electric »

General Electric down 3%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

  • 02

    Oct

GPC

Genuine Parts

$81.69

-1.27 (-1.53%)

08:47
07/21/17
07/21
08:47
07/21/17
08:47
Upgrade
Genuine Parts rating change  »

Genuine Parts upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLB

Schlumberger

$67.02

-0.42 (-0.62%)

08:46
07/21/17
07/21
08:46
07/21/17
08:46
Hot Stocks
Schlumberger says expects to double SPM revenue over next two years »

Says has invested $4.3B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

GE

General Electric

$26.69

-0.25 (-0.93%)

08:45
07/21/17
07/21
08:45
07/21/17
08:45
Hot Stocks
General Electric CFO says 'trending to bottom end' of $1.60-$1.70 FY17 EPS view »

GE CFO Jeff Bornstein…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

  • 02

    Oct

ITW

Illinois Tool Works

$147.12

-0.56 (-0.38%)

08:45
07/21/17
07/21
08:45
07/21/17
08:45
Technical Analysis
Technical Earnings Preview: Illinois Tool Works in uptrend ahead of news »

The shares have been in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

XRT

S&P Retail Index SPDR

$40.59

0.09 (0.22%)

, PAA

Plains All American

$26.47

-0.16 (-0.60%)

08:45
07/21/17
07/21
08:45
07/21/17
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

XRT

S&P Retail Index SPDR

$40.59

0.09 (0.22%)

PAA

Plains All American

$26.47

-0.16 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 08

    Nov

SLB

Schlumberger

$67.02

-0.42 (-0.62%)

08:41
07/21/17
07/21
08:41
07/21/17
08:41
Hot Stocks
Schlumberger says all U.S. product lines profitable in Q2 »

Says expect high demand…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

HIMX

Himax

$8.86

0.34 (3.99%)

08:41
07/21/17
07/21
08:41
07/21/17
08:41
Downgrade
Himax rating change  »

Himax downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 05

    Sep

SLM

Sallie Mae

$10.98

-0.83 (-7.03%)

08:41
07/21/17
07/21
08:41
07/21/17
08:41
Recommendations
Sallie Mae analyst commentary  »

Sallie Mae shares should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLB

Schlumberger

$67.02

-0.42 (-0.62%)

08:38
07/21/17
07/21
08:38
07/21/17
08:38
Hot Stocks
Schlumberger says 'confident' in delivering free cash flow target for 2017 »

Comments from Q2 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

EXPI

eXp World Holdings

$2.95

-0.04 (-1.34%)

08:36
07/21/17
07/21
08:36
07/21/17
08:36
Initiation
eXp World Holdings initiated  »

eXp World Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CXDC

China XD Plastics

$4.70

-0.025 (-0.53%)

08:35
07/21/17
07/21
08:35
07/21/17
08:35
Hot Stocks
China XD Plastics signs investment agreements for $614M in Harbin, China »

China XD Plastics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAAP

Advanced Accelerator

$41.13

0.56 (1.38%)

08:35
07/21/17
07/21
08:35
07/21/17
08:35
Hot Stocks
Advanced Accelerator: CHMP opinion recommending approval of 177Lu oxodotreotide »

Advanced Accelerator…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNB

F.N.B.

$13.59

-0.56 (-3.96%)

, YDKN

Acquired by FNB

08:35
07/21/17
07/21
08:35
07/21/17
08:35
Recommendations
F.N.B., Acquired by FNB analyst commentary  »

F.N.B. weakness overdone,…

FNB

F.N.B.

$13.59

-0.56 (-3.96%)

YDKN

Acquired by FNB

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OFG

OFG Bancorp

$9.85

-0.1 (-1.01%)

08:34
07/21/17
07/21
08:34
07/21/17
08:34
Earnings
OFG Bancorp reports Q2 EPS 30c, consensus 27c »

OFG Bancorp reports Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

ENDP

Endo

$12.32

0.24 (1.99%)

08:32
07/21/17
07/21
08:32
07/21/17
08:32
Hot Stocks
Endo closing Huntsville manufacturing and distribution facilities »

Endo will be ceasing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

ADS

Alliance Data

$238.62

-24.91 (-9.45%)

08:30
07/21/17
07/21
08:30
07/21/17
08:30
Recommendations
Alliance Data analyst commentary  »

Alliance Data weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 05

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.